A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors

被引：0
|
作者：
Schwartz, G. K.
Robertson, S.
Shen, A.
Wang, E.
Pace, L.
Dials, H.
Mendelson, D.
Shannon, P.
Gordon, M.
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Exelixis Inc, San Francisco, CA USA
[3] Premier Oncol, Scottsdale, AZ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3513
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Phase I study of TAS-115, a novel oral multi-kinase inhibitor, in patients with advanced solid tumors
    Toshihiko Doi
    Nobuaki Matsubara
    Akira Kawai
    Norifumi Naka
    Shunji Takahashi
    Hiroji Uemura
    Noboru Yamamoto
    Investigational New Drugs, 2020, 38 : 1175 - 1185
  • [22] Phase I study of TAS-115, a novel oral multi-kinase inhibitor, in patients with advanced solid tumors
    Doi, Toshihiko
    Matsubara, Nobuaki
    Kawai, Akira
    Naka, Norifumi
    Takahashi, Shunji
    Uemura, Hiroji
    Yamamoto, Noboru
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (04) : 1175 - 1185
  • [23] Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors
    Schwartz, Gary K.
    Carvajal, Richard D.
    Midgley, Rachel
    Rodig, Scott J.
    Stockman, Paul K.
    Ataman, Ozlem
    Wilson, David
    Das, Shampa
    Shapiro, Geoffrey I.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (02) : 370 - 380
  • [24] Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors
    Gary K. Schwartz
    Richard D. Carvajal
    Rachel Midgley
    Scott J. Rodig
    Paul K. Stockman
    Ozlem Ataman
    David Wilson
    Shampa Das
    Geoffrey I. Shapiro
    Investigational New Drugs, 2013, 31 : 370 - 380
  • [25] Phase I study of cediranib, an oral, highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors
    Yamamoto, Noboru
    Yamada, Yasuhide
    Yamada, Kazuhiko
    Nokihara, Hiroshi
    Fujiwara, Yutaka
    Hirata, Taizo
    Yamamoto, Nobuyuki
    Boku, Narikazu
    Shin, Eisei
    Tamura, Tomohide
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3417S - 3418S
  • [26] A PHASE I DOSE-ESCALATION STUDY OF EMD 1214063, AN ORAL SELECTIVE CMET INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS
    Naing, A.
    Falchook, G. S.
    Fu, S.
    Amin, H. M.
    Piha-Paul, S. A.
    Hong, D. S.
    Tsimberidou, A. M.
    Wheler, J. J.
    Janku, F.
    Klevesath, M. B.
    Jego, V.
    Johne, A.
    Kurzrock, R.
    ANNALS OF ONCOLOGY, 2012, 23 : 21 - 21
  • [27] Pharmacodynamics (pd) of XL880, a novel spectrum selective kinase inhibitor (SSKI), administered orally to patients (pts) with advanced solid tumors (AST)
    LoRusso, P.
    Appleman, L.
    Zhu, A.
    Shapiro, G.
    Fox, L.
    Wolanski, A.
    Hitchcock-Bryan, S.
    Malburg, L.
    Eder, J.
    EJC SUPPLEMENTS, 2006, 4 (12): : 124 - 124
  • [28] A phase I study of oral ixabepilone in patients with advanced solid tumors
    Deeken, John F.
    Marshall, John L.
    Pishvaian, Michael J.
    Hwang, Jimmy
    Ahlers, Christoph M.
    Clemens, Pamela L.
    Parker, Susan M.
    Iacono, Lisa
    LoRusso, Patricia M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (05) : 1071 - 1078
  • [29] Phase I study of oral rigosertib in patients with advanced solid tumors
    Bowles, Daniel W.
    Diamond, Jennifer Robinson
    Lam, Elaine Tat
    Messersmith, Wells A.
    Weekes, Colin D.
    Leong, Stephen
    Gore, Lia
    Lieu, Christopher Hanyoung
    Freas, Elizabeth
    Ren, Chen
    Wilhelm, Francois
    Eckhardt, S. Gail
    Jimeno, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [30] A phase I study of oral ixabepilone in patients with advanced solid tumors
    John F. Deeken
    John L. Marshall
    Michael J. Pishvaian
    Jimmy Hwang
    Christoph M. Ahlers
    Pamela L. Clemens
    Susan M. Parker
    Lisa Iacono
    Patricia M. LoRusso
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 1071 - 1078
12345